Clinical Corner: New Data From Xeltis Bioabsorbable Heart Repair Devices Headlines Trial News
Medtech Insight's Clinical Corner highlights recent R&D news and developments in ongoing clinical trials of early, late-stage and approved medical devices. This installment includes news on Abbott's Xience drug-eluting coronary stents, Xeltis' bioabsorbable devices for congenital heart defects, NeuroMetrix's Quell pain therapy, and CytoSorbents' blood purifier to treat inflammation in surgery patients.
You may also be interested in...
It may still be early days but Xeltis' second product from its Endogenous Tissue Restoration platform technology, an aortic valve scaffold, is showing promising results in animal studies. The data, presented at EuroPCR, showed that the bioresorbable aortic valve had good hemodynamic performance and fully functional valves in vivo six months after implantation.
Transcutaneous electrical nerve stimulation reduced patients’ reliance on pain drugs over two months.
CytoSorbents is sponsoring the REFRESH I trial of its CytoSorb extracorporeal cytokine adsorber in the US, which the company hopes will support approval of a pivotal trial of the device for reducing reduce plasma free hemoglobin and cytokines in patients undergoing complex cardiac surgery.